Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1393926-50-5

C19H23N3O3S is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1393926-50-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1393926-50-5 Structure

  • Basic information

    1. Product Name: C19H23N3O3S
    2. Synonyms:
    3. CAS NO:1393926-50-5
    4. Molecular Formula:
    5. Molecular Weight: 373.476
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1393926-50-5.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C19H23N3O3S(CAS DataBase Reference)
    10. NIST Chemistry Reference: C19H23N3O3S(1393926-50-5)
    11. EPA Substance Registry System: C19H23N3O3S(1393926-50-5)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1393926-50-5(Hazardous Substances Data)

1393926-50-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1393926-50-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,3,9,2 and 6 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1393926-50:
(9*1)+(8*3)+(7*9)+(6*3)+(5*9)+(4*2)+(3*6)+(2*5)+(1*0)=195
195 % 10 = 5
So 1393926-50-5 is a valid CAS Registry Number.

1393926-50-5Downstream Products

1393926-50-5Relevant articles and documents

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Sarabu, Ramakanth,Bizzarro, Fred T.,Corbett, Wendy L.,Dvorozniak, Mark T.,Geng, Wanping,Grippo, Joseph F.,Haynes, Nancy-Ellen,Hutchings, Stanley,Garofalo, Lisa,Guertin, Kevin R.,Hilliard, Darryl W.,Kabat, Marek,Kester, Robert F.,Ka, Wang,Liang, Zhenmin,Mahaney, Paige E.,Marcus, Linda,Matschinsky, Franz M.,Moore, David,Racha, Jagdish,Radinov, Roumen,Ren, Yi,Qi, Lida,Pignatello, Michael,Spence, Cheryl L.,Steele, Thomas,Tengi, John,Grimsby, Joseph

, p. 7021 - 7036 (2012)

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1393926-50-5